A Phase 3, Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of Shp640 (Pvp-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension in the Treatment of Adenoviral Conjunctivitis
Research payments
$111,162
Through program year 2020, $111,162 in research payments was reported against A Phase 3, Multi-Center, Randomized, Double-Masked Study to Evaluate the Clinical Efficacy and Safety of Shp640 (Pvp-Iodine 0.6% and Dexamethasone 0.1%) Ophthalmic Suspension in the Treatment of Adenoviral Conjunctivitis, across 21 payments, paid by Takeda Pharmaceuticals U.S.A., Inc..
- Paid by
- Takeda Pharmaceuticals U.S.A., Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | Research | $111,162 | 21 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Ryan McKinnon Nampa, ID Named on 2 payments
- Jing-Wei Huang Saint Louis, MO Named on 2 payments
- Sherif El Harazi Glendale, CA Named on 1 payment
- Bruce Segal Delray Beach, FL Named on 1 payment
- Jennifer Fogt Columbus, OH Named on 1 payment
- Omar Benitez Miami, FL Named on 1 payment
- Bernard Perez Tampa, FL Named on 1 payment
- Karen Klugo Cincinnati, OH Named on 1 payment
- Kent Wellish Las Vegas, NV Named on 1 payment
- Stanley Block Bardstown, KY Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.